

UCB Pharma

[View the current UCB Pharma Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/10415-UCB+Pharma.html>)

Contact Details:

**Chemin du Foriest
Braine l'Alleud**

Tel: 00 32 2 386 3070

Fax: 00 32 2 386 2704

Email:

**B-1420
Belgium**

Recent Publications by UCB Pharma:



- [Anti-convulsive and anti-epileptic properties of brivaracetam \(ucb 34714\), a high-affinity ligand for the synaptic vesicle protein, SV2A.](#)
BACKGROUND AND PURPOSE: Screening of 12,000 compounds for binding affinity...1st October, 2008
CNS Research, UCB Pharma SA, Braine-l'Alleud, Belgium.- Br J Pharmacol. 2008 Aug;154(8):1662-71. Epub 2008 May 26. ([DOI Direct Link](#))
- [Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.](#)
OBJECTIVE: To characterize levetiracetam pharmacokinetics, identify...26th September, 2008
Pharmacometrics, UCB Pharma SA, Braine-l'Alleud, Belgium.- Clin Pharmacokinet. 2008;47(5):333-41.
- [Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats.](#)
*Levetiracetam (Keppra((R))) is a new generation antiepileptic drug...*30th August, 2008
UCB PHARMA S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.- Brain Res Bull. 2008 Aug 20. ([DOI Direct Link](#))
- [Effect of brivaracetam on cardiac repolarisation--a thorough QT study.](#)
OBJECTIVES: To assess the effect on cardiac repolarisation of the...8th July, 2008
Exploratory Development, UCB Pharma SA, Braine-l'Alleud, Belgium.- Curr Med Res Opin. 2008 Aug;24(8):2327-37. Epub 2008 Jul 3. ([DOI Direct Link](#))
- [SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.](#)

- SV2A, a synaptic vesicle protein, has been recently identified as a...13th June, 2008
CNS Research, UCB PHARMA SA, Chemin du Foriest R9, Braine-l'Alleud,- Neuropharmacology. 2008 Mar;54(4):715-20. Epub 2007 Dec 8. ([DOI Direct Link](#))
- [Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study.](#)
*Background: Nonantiarrhythmic drugs may have the potential to prolong the...*18th March, 2008
Clinical Pharmacology, UCB Pharma SA, Braine-l'Alleud, Belgium.- Clin Ther. 2008 Feb;30(2):260-70. ([DOI Direct Link](#))
 - [Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine.](#)
*Competition for uptake and/or efflux transporters can be responsible for...*28th February, 2008
Non Clinical Development Department, UCB Pharma S.A., 21 rue de Neuilly,- Fundam Clin Pharmacol. 2008 Feb;22(1):19-23. Epub 2007 Nov 15. ([DOI Direct Link](#))
 - [Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study.](#)
*OBJECTIVE: To conduct a thorough QT study of levocetirizine, a...*15th February, 2008
Clinical Pharmacology, UCB Pharma SA, Chemin du Foriest 1420,- Eur J Clin Pharmacol. 2007 Nov;63(11):1011-7. Epub 2007 Sep 21. ([DOI Direct Link](#))
 - [Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects.](#)
*This study was designed to investigate the human absorption, disposition,...*9th February, 2008
UCB Pharma SA,- Drug Metab Dispos. 2008 Jan;36(1):36-45. Epub 2007 Oct 1. ([DOI Direct Link](#))
 - [Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?](#)
*In this review, the major enzyme systems involved in vivo in the oxidative...*4th January, 2008
UCB Pharma, Non Clinical Development, Nanterre, France.- Fundam Clin Pharmacol. 2007 Oct;21(5):467-80. ([DOI Direct Link](#))
 - [Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.](#)
*PURPOSE: To determine whether levetiracetam (LEV) affects plasma...*3rd January, 2008
UCB Pharma SA, Chemin du Foriest, Braine-l'Alleud, Belgium.- Epilepsia. 2007 Nov;48(11):2111-5. Epub 2007 Jul 25. ([DOI Direct Link](#))
 - [Factors affecting the relative importance of amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans.](#)
*The monooxygenases and the amine oxidases (AOs) are the major enzyme...*6th December, 2007
UCB Pharma, Non Clinical Development, Nanterre, France.- J Neural Transm. 2007;114(6):787-91. Epub 2007 Mar 31. ([DOI Direct Link](#))
 - [Drug metabolism in the paediatric population and in the elderly.](#)
*This review focuses on one of the key factors accounting for differences...*31st October, 2007
UCB Pharma, 21 rue de Neuilly, 92003 Nanterre Cedex, France.- Drug Discov Today. 2007 Aug;12(15-16):599-610. Epub 2007 Aug 2. ([DOI Direct Link](#))
 - [Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists.](#)
*The discovery and optimization of a novel class of potent CCR3 antagonists...*2nd October, 2007
UCB Pharma SA, R&D, Chemin du Foriest, B-1420 Braine-L'Alleud, Belgium.- Bioorg Med Chem Lett. 2007 Aug 1;17(15):4228-31. Epub 2007 May 17. ([DOI Direct Link](#))
 - [Population pharmacokinetics of levetiracetam in Japanese and Western adults.](#)
*OBJECTIVE: To assess the population pharmacokinetics of levetiracetam, a...*27th September, 2007
Global Pharmacometrics, UCB Pharma SA, Braine-l'Alleud, Belgium.- Clin Pharmacokinet. 2007;46(6):503-12.

- [European Pharmaceutical Pricing & Reimbursement](#)
Pharmalicensing: Oct 5 2008 8:31PM Matching: ucb pharma
- [ALSO NOTED: Cephalon, NitroMed make cuts jobs; IonGate gains funds; and much more](#)
FierceBiotech: Oct 3 2008 9:06AM Matching: ucb pharma
- [Inaugural BIOTECanada-UCB Pharma National Health Innovation Patient Advocacy Awards Granted](#)
Therapeutics Daily: Oct 2 2008 9:35PM Matching: ucb pharma
- [Final Call to Register for BioPartnering Europe \(BPE\)](#)
Reuters: Oct 2 2008 9:37PM Matching: ucb pharma
- [Final Call to Register for BioPartnering Europe \(BPE\)](#)
Business Wire via Yahoo!: Oct 2 2008 9:29PM Matching: ucb pharma
- [DIARY - Western European Corporate events from Oct 01, 2008](#)
Forbes.com: Oct 1 2008 6:52AM Matching: ucb pharma
- [UCB Scholarship Program Awards \\$300,000 to Students Living with Crohn's Disease](#)
KRON4: Sep 30 2008 7:04AM Matching: ucb pharma
- [UCB Scholarship Program Awards \\$300,000 to Students Living with Crohn's Disease](#)
Montana's News Station: Sep 30 2008 12:01AM Matching: ucb pharma
- [UCB Scholarship Program Awards \\$300,000 to Students Living with Crohn's Disease](#)
KSLA: Sep 29 2008 4:10PM Matching: ucb pharma
- [Indian scientists to partner in making genetic cancer drug](#)
Livemint.com: Sep 28 2008 7:28PM Matching: ucb pharma
- [UCB Pharma withdraws its marketing authorisation application for Lacosamide Pain UCB Pharma](#)
Biotech Intelligence: Sep 26 2008 5:30PM Matching: ucb pharma
- [CORRECTING and REPLACING Inaugural BIOTECanada-UCB Pharma National Health Innovation Patient Advocacy Awards G](#)
Forbes.com: Sep 25 2008 3:37PM Matching: ucb pharma
- [CORRECTING and REPLACING Inaugural BIOTECanada-UCB Pharma National Health Innovation Patient Advocacy Awards G](#)
Genetic Engineering News: Sep 25 2008 3:29PM Matching: ucb pharma
- [CORRECTING and REPLACING Inaugural BIOTECanada-UCB Pharma National Health Innovation Patient Advocacy Awards G](#)
Earthtimes.org: Sep 25 2008 3:17PM Matching: ucb pharma
- [Inaugural BIOTECanada-UCB Pharma National Health Innovation Patient Advocacy Awards Granted](#)
Business Wire: Sep 25 2008 11:24AM Matching: ucb pharma

UCB Pharma Patents:



- 7419659- [Expression control using variable intergenic sequences](#)
- 7402662- [Antibody molecules specific to human tumor necrosis factor alpha](#)
- 7355011- [Biological products](#)

- 7300765- [SC6 for diagnosis of cancers](#)
- 7297760- [Cancer associated protein](#)
- 7273744- [Heparanase-like polypeptides](#)
- 7169399- [Non-toxic double mutant forms of pertussis toxin as adjuvants](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:Peter.Barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

